Eli Lilly's Weight Loss Pill: Clinical Trials Show 29% Reduction
New data reveals that orforglipron, Eli Lilly's oral weight-loss drug candidate, exhibited significant weight reduction in clinical studies, presenting a possible new avenue for those struggling with obesity and associated conditions. The drug is anticipated to be available in 2024.
On Thursday, December 7, 2023, Eli Lilly revealed that its experimental oral drug, orforglipron, resulted in weight loss of up to 29% during clinical trials. The clinical trials included participants who were obese or overweight and had at least one weight-related health condition. The most substantial weight reduction was observed in patients receiving the highest dose of orforglipron.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
The drug functions by activating the GLP-1 receptor, akin to widely used injectable weight-loss drugs like Wegovy and Mounjaro, both also manufactured by Eli Lilly. Health tracking apps like Shotlee can help monitor progress with such medications. However, orforglipron is administered orally, potentially providing a more convenient option for patients.